相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats
Cristina Meregalli et al.
EUROPEAN JOURNAL OF PAIN (2010)
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients
Roser Velasco et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2010)
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients
Alessandro Corso et al.
LEUKEMIA RESEARCH (2010)
Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons
Inigo Casafont et al.
NEUROTOXICITY RESEARCH (2010)
Induction of angiogenesis by normal and malignant plasma cells
Dirk Hose et al.
BLOOD (2009)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Topical Analgesic Combinations for Bortezomib Neuropathy
Eric E. Prommer
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2009)
Bortezomib: A novel chemotherapeutic agent for hematologic malignancies
Kyle N. Utecht et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Andreas A. Argyriou et al.
BLOOD (2008)
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells - A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition
Marianne S. Poruchynsky et al.
CELL CYCLE (2008)
Immune-mediated neuropathies in myeloma patients treated with bortezomib
Sabrina Ravaglia et al.
CLINICAL NEUROPHYSIOLOGY (2008)
Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies
S. B. Park et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
A. Gilardini et al.
CURRENT MEDICINAL CHEMISTRY (2008)
From bench to bedside: A case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol
Leslie A. Colvin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy
Vinay Chaudhry et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity
Francesca Lanzani et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board
Joseph D. Tariman et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale
Guido Cavaletti et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2007)
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative sensory findings in patients with bortezomib-induced pain
Juan P. Cata et al.
JOURNAL OF PAIN (2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
A. K. Stewart et al.
LEUKEMIA (2007)
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Guido Cavaletti et al.
EXPERIMENTAL NEUROLOGY (2007)
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
Ashraf Badros et al.
CANCER (2007)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
Maria-Victoria Mateos et al.
BLOOD (2006)
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
Linda Mileshkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein
Masahiro Waza et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
M. D. Stubblefield et al.
CLINICAL ONCOLOGY (2006)
Antimyeloma activity of heat shock protein-90 inhibition
CS Mitsiades et al.
BLOOD (2006)
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
JR Berenson et al.
CANCER (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
